News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Asahi Kasei Pharma America Initiates Phase 3 Clinical Trial for ART-123 in Severe Sepsis Patients With Coagulopathy


10/31/2012 7:32:54 AM

WALTHAM, Mass.--(BUSINESS WIRE)--Asahi Kasei Pharma America Corp. (AKP America) today announced the initiation of an 800-patient Phase 3 clinical trial for ART-123 (recombinant human thrombomodulin, marketed as Recomodulin® in Japan) in severe sepsis patients with coagulopathy. The Phase 3 trial follows a successful 750-patient randomized, double-blind, placebo-controlled Phase 2b study that assessed the safety and efficacy of ART-123.

Read at BioSpace.com

comments powered by Disqus
 
 
Sepsis

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES